PAVmed elects stock payment of $4.7M fees from Lucid Diagnostics

PAVmed Inc.

PAVmed received $4,675,256 of fees/reimbursements from Lucid Diagnostics via 3,331,771 shares of Lucid common stock.
Lucid Diagnostics is a majority-owned subsidiary of PAVmed.
Transaction described in more detail in Lucid Diagnostics' Form 8-K filed January 30, 2024.

item 8.01 item 9.01

PAVmed Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-004350

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.